Pharmaceuticals in China industry profile provides top-line qualitative and quantitative summary information including: market size (value 2018-23, and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values refer to the value generated by market players.
The Chinese pharmaceuticals market registered revenue of $161 billion in 2023, representing a compound annual growth rate (CAGR) of 8.2% between 2018 and 2023.
China dominated the Asia-Pacific pharmaceuticals market in 2023, accounting for the largest share of 41.1% in 2023.
Scope
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the pharmaceuticals market in China
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in China
Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the China pharmaceuticals market with five year forecasts
Reasons to Buy
What was the size of the China pharmaceuticals market by value in 2023?
What will be the size of the China pharmaceuticals market in 2028?
What factors are affecting the strength of competition in the China pharmaceuticals market?
How has the market performed over the last five years?
What are the main segments that make up China's pharmaceuticals market?
1 Executive Summary
1.1. Market value
1.2. Market value forecast
1.3. Geography segmentation
1.4. Market rivalry
1.5. Competitive landscape
2 Market Overview
2.1. Market definition
2.2. Market analysis
3 Market Data
3.1. Market value
4 Market Segmentation
4.1. Geography segmentation
5 Market Outlook
5.1. Market value forecast
6 Five Forces Analysis
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 Competitive Landscape
7.1. Who are the leading players?
7.2. What strategies do leading players follow?
7.3. What are the recent developments in the market?
8 Company Profiles
8.1. CSPC Pharmaceutical Group Ltd
8.2. Shanghai Pharmaceuticals Holding Co Ltd
8.3. Sinopharm Group Co Ltd
8.4. Jiangsu Hengrui Medicine Co Ltd
9 Macroeconomic Indicators
9.1. Country data
10 Appendix
10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine
List of Tables
Table 1: China pharmaceuticals market value: $ billion, 2018-23
Table 2: China pharmaceuticals market geography segmentation: $ billion, 2023
Table 3: China pharmaceuticals market value forecast: $ billion, 2023-28
Table 4: CSPC Pharmaceutical Group Ltd: Key Facts
Table 5: CSPC Pharmaceutical Group Ltd: Annual Financial Ratios
Table 6: CSPC Pharmaceutical Group Ltd: Key Employees
Table 7: Shanghai Pharmaceuticals Holding Co Ltd: Key Facts
Table 8: Shanghai Pharmaceuticals Holding Co Ltd: Annual Financial Ratios
Table 9: Shanghai Pharmaceuticals Holding Co Ltd: Key Employees
Table 10: Sinopharm Group Co Ltd: Key Facts
Table 11: Sinopharm Group Co Ltd: Annual Financial Ratios
Table 12: Sinopharm Group Co Ltd: Key Employees
Table 13: Jiangsu Hengrui Medicine Co Ltd: Key Facts
Table 14: Jiangsu Hengrui Medicine Co Ltd: Annual Financial Ratios
Table 15: Jiangsu Hengrui Medicine Co Ltd: Key Employees
Table 16: China Size of Population (million), 2019-23
Table 17: China Real GDP (constant 2010 prices, $ billion), 2019-23
Table 18: China GDP (current prices, $ billion), 2019-23
Table 19: China Inflation, 2019-23
Table 20: China Consumer Price Index (absolute), 2019-23
Table 21: China Exchange Rate, 2018-23
List of Figures
Figure 1: 220 Laboratories Inc: Deal Activity by Deal Type - Volume (2020 - YTD*2024)
Figure 2: 220 Laboratories Inc: Private Equity and Ownership Volume and Value Trend (2020 - YTD*2024)
Figure 3: 220 Laboratories Inc: Private Equity and Ownership Volume by Deal Type (2020 - YTD*2024)